Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups
Key facts
- Who runs it
- Szeged University
- Where
- Hungary1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 500 people, planned
- Started
- 1 Sept 2024
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional, 5 groups
- Treatments tested
- recFSH
- HCG injection
- Clomiphene Citrate 50 mg
- Record updated
- 16 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- abnormal sperm analysis result, APHRODITE 2,3,4 categories
Who cannot take part
- non-obstructive azoospermia due to genetical defects (Klinefelter-syndrome, AZFa, AZFb microdeletion syndrome etc)
- obstructive azoospermia
- problems with the administration of subcutaneous injections
- disagreement
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Men enrolled in the study are assigned to each APHRODITE group. Group 2,3,4 are treated with either gonadotropin preparations or clompihene-citrate (except group 4). The type of the treatment (gonadotropin vs clomiphene) is randomized. After treatment, hormonal measurements, spermiogram and DNA fragmentation tests are repeated, allowing for analysis of the outcome.
The 5 groups in the trial
- APHRODITE category 2 treated with gonadotropinTreatment being tested
subcutaneous recFSH 3x150NE weekly for 12 weeks
Treatment: recFSH
- APHRODITE category 2 treated with clomiphene-citrateTreatment being tested
per os 50mg clomiphene-citrate daily for 12 weeks
Treatment: Clomiphene Citrate 50 mg
- APHRODITE category 3 treated with gonadotropinTreatment being tested
subcutaneous recFSH 3x150NE weekly and subcutaneous hCG 2x5000NE weekly for 12 weeks
Treatment: recFSH and HCG injection
- APHRODITE category 3 treated with clomiphene-citrateTreatment being tested
per os 50mg clomiphene-citrate daily for 12 weeks
Treatment: Clomiphene Citrate 50 mg
- APHRODITE category 4 treated with gonadotropinTreatment being tested
subcutaneous hCG 2x5000NE weekly for 12 weeks, if FSH level drops below 1.5 IU/l, subcutaneous recFSH 3x150NE weekly added
Treatment: recFSH and HCG injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 April 2026